Research progress in non-small cell lung cancer-related anemia

Liubing XIONG,Lei CHEN,Qiuli LI,Hao ZHANG
DOI: https://doi.org/10.3969/j.issn.2095-3097.2014.02.003
2014-01-01
Abstract:Anemia is very common in patients with non-small cell lung cancer (NSCLC ), but the exact cause of anemia in this subset of patients remains unclear,possibly due to complex clinical settings.Patients with anemia usually presented with fatigue,which significantly compromise treatment outcome and undermine their quality of life (QOL).Studies have shown that anemia is tightly linked to drug resistance through increasing invasiveness of cancer cell,thereby reducing the efficacy of radiotherapy and chemotherapy for patients with NSCLC.It is reported that anemia in NSCLC patients is associated with cancer progression,as well as the side effects of radiotherapy and chemotherapy,and the dynamic change of hemoglobin level in patients with anemia might be recko-ned as an indicator of treatment outcome and prognosis.Effective intervention and treatment of ane-mia is closely related to the prognosis of patients with NSCLC.The clinical use of Erythropoietin (EPO)in cancer patients is still controversial,however,when utilized in conjunction with chemo-therapy,it can improve the quality of life in patients with NSCLC,which indicating that further pro-spective clinical study to validate its role in these patients is needed.
What problem does this paper attempt to address?